{"id":"NCT04458857","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-15","primaryCompletion":"2024-03-13","completion":"2024-03-13","firstPosted":"2020-07-07","resultsPosted":"2025-04-16","lastUpdate":"2025-06-22"},"enrollment":235,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Fremanezumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fremanezumab Dose A","type":"EXPERIMENTAL"},{"label":"Fremanezumab Dose B","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM).\n\nSecondary objectives are to further demonstrate the efficacy of fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and tolerability of fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to fremanezumab.\n\nThe total duration of the study is planned to be up to 51 months.","primaryOutcome":{"measure":"Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug","timeFrame":"Baseline (Day -28 to Day -1), up to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-1.4,"sd":0.39},{"arm":"Fremanezumab","deltaMin":-2.5,"sd":0.38}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0210"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":89,"countries":["United States","Canada","Finland","Germany","Israel","Italy","Netherlands","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":112},"commonTop":["Nasopharyngitis","Injection site erythema","COVID-19","Injection site pain","Upper respiratory tract infection"]}}